Biontech Se

Jpt Peptide Technologies Gmbh

Jerini Ag

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-universitat Mainz Ggmbh

Shire Orphan Therapies Gmbh

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Guttenberg-universitat Mainz Gemeinnuizige Gmbh

Biontech Ag

Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh

Karsten Schnatbaum

Ulf Reimer

Gerd Hummel

Dirk Scharn

Elsa Locardi

Ugur Sahin

Ulrich Reineke

Thomas Polakowski

Markus Fiedler

Uwe Richter

Hans-Ulrich Schmoldt

Matin Daneschdar

Matthias Paschke

Christoph Gibson

Jochen Pfeifer

Laura-Marie Kring (née Plum)

Laura Marie Kring

Thomas Tradler

Laura-Marie Plum

The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3&#x3b5;). These molecules compete with CD3&#x3b5; for binding to a CD3&#x3b5; binding domain. e.g. a CD3&#x3b5; binding domain of an antibody, and are capable of detecting antibodies against CD3&#x3b5;. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3&#x3b5; antibody purification and the detection of anti-CD3&#x3b5; antibodies in biological samples.

Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof

The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

Peptide mimotopes of claudin 18.2 and uses thereof

The present invention is related to compound of the formula (I): or a pharmacologically acceptable salt, solvate, or hydrate thereof, wherein A is a 6-membered heteroaryl having from 1 to 3 heteroatoms, each independently selected from N or O and the other substituents are defined as in the claims. 

8-oxy-quinoline derivatives as bradykinin B2 receptor modulators

The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22 are individually and independently selected from the group comprising H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, alkoxyl, substituted alkoxyl, aryloxy, substituted aryloxy, arylalkyloxy, substituted arylalkyloxy, acyloxy, substituted acyloxy, halogen, hydroxyl, nitro, cyano, acyl, substituted acyl, mercapto, alkylthio, substituted alkylthio, amino, substituted amino, alkylamino, substituted alkylamino, bisalkyl amino, substituted bisalkyl amino, cyclic amino, substituted cyclic amino, carbamoyl (&#x2014;CONH), substituted carbamoyl, carboxyl, carbamate, alkoxycarbonyl, substituted alkoxycarbonyl, acylamino, substituted acylamino, sulfamoyl (&#x2014;SONH), substituted sulfamoyl, haloalkyl, haloalkyloxy, &#x2014;C(O)H, trialkylsilyl and azido. 

C5a receptor antagonists

The invention relates to a C5a receptor antagonist of structure (I), wherein X1 is a radical having a mass of about 1-300 and stands for R5-, R5-CO&#x2014;, R5-N(R6)-CO&#x2014;, R5-O&#x2014;CO&#x2014;, R5-SO&#x2014;, R5-N(R6)-SO&#x2014;, R5-N(R6)-, R5-N(R6)-CS&#x2014;, R5-N(R6)-C(NH)&#x2014;, R5-CS&#x2014;, R5-P(O)OH&#x2014;, R5-B(OH)&#x2014; or R5-CH&#x2550;N&#x2014;O&#x2014;CH&#x2014;CO&#x2014;, wherein R5/R6 represent H, F, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, arylalkyl, substituted arylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl, substituted acyl, alkoxy, alkoxyalkyl, substituted alkoxyalkyl, aryloxyalkyl or substituted aryloxyalkyl; X2=radical (biological bonding properties of a mimicrying phenylalanine unit); X3/X4=spacer (amino acids, amino-acid analogs and amino-acid derivatives); X5=radical (biological bonding properties of a mimicrying cyclohexylalanine or homoleucine unit); X6=radical (biological bonding properties of a mimicrying tryptophan unit); X7=radical (biological bonding properties of a mimicrying norleucine or phenylalanine unit), a chemical bond being formed between X3 and X7.

Growing community of inventors

Berlin, Germany

Karsten Schnatbaum